Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Alibaba (BABA) Misses Q2 EPS by 220c